Axsome Therapeutics Management
Management criteria checks 2/4
Axsome Therapeutics' CEO is Herriot Tabuteau, appointed in Jan 2012, has a tenure of 12.83 years. total yearly compensation is $9.90M, comprised of 7.6% salary and 92.4% bonuses, including company stock and options. directly owns 0.015% of the company’s shares, worth $709.97K. The average tenure of the management team and the board of directors is 6.5 years and 9.9 years respectively.
Key information
Herriot Tabuteau
Chief executive officer
US$9.9m
Total compensation
| CEO salary percentage | 7.6% |
| CEO tenure | 12.8yrs |
| CEO ownership | 0.01% |
| Management average tenure | 6.5yrs |
| Board average tenure | 9.9yrs |
Recent management updates
Recent updates
Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell
Nov 12Axsome: AXS-07 And Its Upcoming Second PDUFA
Oct 15Getting In Cheap On Axsome Therapeutics, Inc. (NASDAQ:AXSM) Might Be Difficult
Sep 06
Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
Aug 06Axsome Therapeutics: Lots Of Moving Parts
Jul 23Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?
Jul 02Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
May 10Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Apr 13Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Mar 17Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges
Feb 21Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce
Dec 27Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Dec 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Sep 12Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Aug 08Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts
May 13Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 03Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?
Mar 01Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?
Nov 14Axsome Therapeutics: Clear Path Ahead For AXS07
Oct 05Axsome to resubmit marketing application for migraine therapy in Q3 2023
Sep 29Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity
Sep 16Axsome begins enrolling in late-stage study of migraine drug AXS-07
Sep 01Axsome gains 19% as FDA approves depression therapy
Aug 19Axsome Therapeutics Q2 2022 Earnings Preview
Aug 08Axsome: Breaking Bearish Trend
Jul 26Axsome: One Step At A Time
Jul 01Axsome And AXS-05: A Special Situation
May 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$311m |
| Jun 30 2024 | n/a | n/a | -US$309m |
| Mar 31 2024 | n/a | n/a | -US$296m |
| Dec 31 2023 | US$10m | US$750k | -US$239m |
| Sep 30 2023 | n/a | n/a | -US$202m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$159m |
| Dec 31 2022 | US$8m | US$685k | -US$187m |
| Sep 30 2022 | n/a | n/a | -US$160m |
| Jun 30 2022 | n/a | n/a | -US$150m |
| Mar 31 2022 | n/a | n/a | -US$141m |
| Dec 31 2021 | US$8m | US$685k | -US$130m |
| Sep 30 2021 | n/a | n/a | -US$126m |
| Jun 30 2021 | n/a | n/a | -US$114m |
| Mar 31 2021 | n/a | n/a | -US$100m |
| Dec 31 2020 | US$7m | US$575k | -US$103m |
| Sep 30 2020 | n/a | n/a | -US$99m |
| Jun 30 2020 | n/a | n/a | -US$95m |
| Mar 31 2020 | n/a | n/a | -US$90m |
| Dec 31 2019 | US$5m | US$435k | -US$68m |
| Sep 30 2019 | n/a | n/a | -US$53m |
| Jun 30 2019 | n/a | n/a | -US$42m |
| Mar 31 2019 | n/a | n/a | -US$37m |
| Dec 31 2018 | US$1m | US$435k | -US$31m |
| Sep 30 2018 | n/a | n/a | -US$29m |
| Jun 30 2018 | n/a | n/a | -US$27m |
| Mar 31 2018 | n/a | n/a | -US$26m |
| Dec 31 2017 | US$1m | US$435k | -US$29m |
Compensation vs Market: Herriot's total compensation ($USD9.90M) is above average for companies of similar size in the US market ($USD6.60M).
Compensation vs Earnings: Herriot's compensation has increased whilst the company is unprofitable.
CEO
Herriot Tabuteau (56 yo)
12.8yrs
Tenure
US$9,896,629
Compensation
Dr. Herriot Tabuteau, MD founded Axsome Therapeutics, Inc. in January 2012 and has been its Chief Executive Officer, President and Chairman since January 2012. Dr. Tabuteau served as Interim Principal Fina...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 12.8yrs | US$9.90m | 0.015% $ 710.0k | |
| Chief Financial Officer | 6.5yrs | US$3.57m | 0.087% $ 4.2m | |
| Chief Operating Officer | 9.1yrs | US$4.04m | 0.012% $ 567.7k | |
| General Counsel & Secretary | 2.9yrs | US$3.06m | 0% $ 0 | |
| Chief Commercial Officer | 1.1yrs | no data | no data |
6.5yrs
Average Tenure
46.5yo
Average Age
Experienced Management: AXSM's management team is seasoned and experienced (6.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 12.8yrs | US$9.90m | 0.015% $ 710.0k | |
| Independent Lead Director | 9.9yrs | US$400.34k | 0.35% $ 16.5m | |
| Independent Director | 9.9yrs | US$405.34k | 0.021% $ 1.0m | |
| Independent Director | 1.1yrs | US$417.48k | 0% $ 0 | |
| Independent Director | 9.9yrs | US$427.84k | 0.030% $ 1.4m |
9.9yrs
Average Tenure
56yo
Average Age
Experienced Board: AXSM's board of directors are considered experienced (9.9 years average tenure).